An object of the present invention is to provide a compound exhibiting an excellent drug efficacy as an anti-adenoviral agent, and an anti-adenoviral agent. The present invention provides an anti-adenoviral agent including a compound represented by General Formula [1]

##STR00001##

(in the formula, R.sup.1 represents a hydrogen atom, a halogen atom, an amino group which may be substituted, a monocyclic nitrogen-containing heterocyclic ring group which may be substituted (provided that a nitrogen atom forming the ring is bonded to a carbon atom to which R.sup.1 is bonded), a monocyclic nitrogen- and oxygen-containing heterocyclic ring group which may be substituted (provided that a nitrogen atom forming the ring is bonded to a carbon atom to which R.sup.1 is bonded), a C.sub.1-6 alkoxy group which may be substituted, a hydroxyl group which may be protected, or the like; R.sup.2 represents a hydrogen atom or an amino protecting group; R.sup.3 represents a C.sub.1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; R.sup.4 represents a C.sub.1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; and X represents an oxygen atom or a sulfur atom) or a salt thereof.

Compounds of the general formula (I): ##STR00001##
or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

The present application belongs to the technical field of new energy, in particular to a non-aqueous electrolyte for a lithium ion battery and a lithium ion battery. The non-aqueous electrolyte for a lithium ion battery comprises a non-aqueous organic solvent, a lithium salt, and a spiro compound represented by Structural Formula 1. The compound represented by Structural Formula 1 has the characteristic of sulfonate additives to improve high-temperature storage performance of battery, and also has the characteristic of sulfate additives to improve high-temperature cycle performance of battery. A passivation film is deposited on the surface of positive electrode, and functional group X is further crosslinked to make the coated passivation film more compact and stable, which can effectively improve the electrochemical performance of the electrode, the storage performance and self-discharge performance of the battery.

##STR00001##

This disclosure relates to the use of uridine diphosphate (UDP) derivatives, salts and/or prodrugs thereof for the treatment of inflammatory conditions (e.g., psoriasis) and glaucoma, to prodrugs of UDP derivatives, compositions comprising therapeutically effective amounts of those prodrugs of the UDP derivatives and methods of using those prodrugs for treating various disorders including, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma, and inflammatory conditions, e.g., psoriasis and rheumatoid arthritis.

Provided are: a nucleating agent capable of simultaneously improving the thermal stability and the transparency of a polyolefin resin; a polyolefin-based resin composition containing the same; and a molded article of the composition. The nucleating agent contains a compound represented by Formula (1) below where R.sup.1 to R.sup.4 each independently represent a hydrogen atom or a linear or branched alkyl group having 1 to 9 carbon atoms; R.sup.5 represents an alkanediyl group having 1 to 4 carbon atoms; and M represents a hydrogen atom or a sodium atom. In this nucleating agent, the mass ratio of phosphorus atoms and sodium atoms, P/Na, is in a range of 1.200 to 1.500.

##STR00001##

Provided are a 3,3,3,3-tetramethyl-1,1-spirobiindane-based monophosphine ligand and intermediates thereof, and preparation methods and uses of the same. The monophosphine ligand is a compound represented by formula I or formula I, or an enantiomer, a raceme or a diastereoisomer thereof, including phosphonite ligands, phosphite ligands, phosphoramidite ester ligands, phosphoric acid and phosphonic amide. The monophosphine ligand is prepared with a known 3,3,3,3-tetramethyl-1,1-spirobiindane-7,7-diol derivative as a raw material through a scheme in which the compound presented by formula II acts as an intermediate. The present disclosure provides a novel monophosphine ligand, which can be used as a ligand in a metal-catalysed organic reactions or in directly catalyzing an organic reaction, especially as a chiral monophosphine ligand widely used in many chiral catalytic reactions such as asymmetric addition, asymmetric hydrogenation, asymmetric coupling, and asymmetric allyl alkylation, having economic practicality and industrial application prospects.

##STR00001##

An alkoxy amine compound is provided, which has a chemical structure of: ##STR00001##
wherein each of R.sup.1 is independently H, C.sub.1-6 alkyl group, or C.sub.1-6 alkoxy group; R.sup.2 is C.sub.1-6 alkyl group, R.sup.3 is (C.sub.xH.sub.2x)OH or (C.sub.xH.sub.2x+1), and x is 1 to 8; R.sup.4 is H or C.sub.1-6 alkyl group; R.sup.5 is ##STR00002##
and R.sup.6 is H or C.sub.1-8 alkyl group; R.sup.7 is H or C.sub.1-6 alkyl group, R.sup.8 is ##STR00003##
Ini is a residual group of a radical initiator; and n is an integer of 1 to 10000.

Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.

A particulate nucleating agent provided and includes an aromatic phosphate ester metal salt represented by a predetermined formula, where the following is satisfied: a maximum particle diameter of the particulate nucleating agent is denoted by D.sub.max and a degree of dispersion of the particulate nucleating agent is denoted by D.sub.p, 80 mD.sub.max300 m and 1.0% D.sub.p27.0%.

Provided herein are organophosphates and pharmaceutical compositions comprising said compounds.